Fosun Reports $157 Million of China mRNA Vaccine Sales in 2021

What’s new: Sales of a Chinese version of Pfizer-BioNTech’s Covid-19 mRNA vaccine exceeded 1 billion yuan ($157 million) in 2021, Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (600196.SH) disclosed Wednesday in its annual report.

Fosun is the exclusive partner of Germany’s BioNTech for marketing in Greater China the mRNA vaccine it co-developed with U.S. drug giant Pfizer Inc. Known in China as the Comirnaty vaccine, the product hasn’t been approved for the Chinese mainland and is sold only in Hong Kong, Macao and Taiwan.